|
SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details) (USD $)
|
1 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
Collaborations
|
Dec. 31, 2013
Collaborations
Development event
|
Dec. 31, 2013
Collaborations
Regulatory event
|
Dec. 31, 2013
Collaborations
Product launch event
|
Aug. 31, 2002
Daiichi
|
Dec. 31, 2013
Daiichi
|
Apr. 30, 2013
Daiichi
Milestone achieved
|
Jan. 31, 2012
Daiichi
Milestone achieved
|
Apr. 30, 2010
AstraZeneca worldwide license agreement SYK inhibitors
|
Apr. 30, 2010
AstraZeneca worldwide license agreement SYK inhibitors
Single unit of accounting
item
|
Sep. 25, 2010
AstraZeneca worldwide license agreement SYK inhibitors
Single unit of accounting
|
Sep. 30, 2010
AstraZeneca worldwide license agreement SYK inhibitors
Milestone achieved
|
Jul. 31, 2012
AstraZeneca worldwide license agreement JAK inhibitor
|
Jun. 30, 2012
AstraZeneca worldwide license agreement JAK inhibitor
|
Dec. 31, 2013
AstraZeneca worldwide license agreement JAK inhibitor
Development event
|
Jul. 31, 2012
BerGenBio
|
Jun. 30, 2012
BerGenBio
|
|
| Collaborations | |||||||||||||||||
| Upfront fee received | $ 100,000,000 | $ 1,000,000 | $ 500,000 | ||||||||||||||
| Number of units of accounting | 1 | ||||||||||||||||
| Revenue recognized | 100,000,000 | 25,000,000 | 1,000,000 | 500,000 | |||||||||||||
| Maximum amount of contingent payments receivable | 152,300,000 | 61,200,000 | 53,600,000 | 37,500,000 | |||||||||||||
| Collaborative payment received | 1,400,000 | 750,000 | 5,800,000 | ||||||||||||||
| Cumulative amount of payments earned under collaborative arrangement | $ 7,900,000 | ||||||||||||||||
| Period of collaboration in research phase | 3 years | ||||||||||||||||